# JAKAFI (ruxolitinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ruxolitinib

> The FDA approved JAKAFI (ruxolitinib), sponsored by INCYTE CORP (INCY), on May 1, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | JAKAFI (ruxolitinib) |
| Codes | INCB018424 |
| Sponsor | INCYTE CORP (INCY) https://sec-api.dev/companies/incy/catalysts |
| Indications | [moderate atopic dermatitis](https://sec-api.dev/indications/moderate-atopic-dermatitis), mild to moderate hidradenitis suppurativa, moderate ad, Pancreatic Cancer, [Chronic Graft-versus-host-disease](https://sec-api.dev/indications/chronic-graft-versus-host-disease), Leukemia, [Atopic Dermatitis](https://sec-api.dev/indications/atopic-dermatitis) |
| Modality | small_molecule |
| FDA designations | breakthrough, fast track, orphan, priority review |

## Timeline

### September 21, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215309 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20210921, review_priority PRIORITY; sponsor_name INCYTE CORP; product OPZELURA (RUXOLITINIB PHOSPHATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215309%22

### September 22, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202192 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20210922, review_priority PRIORITY; sponsor_name INCYTE CORP; product JAKAFI (RUXOLITINIB PHOSPHATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202192%22

### July 18, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215309 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20220718, review_priority PRIORITY; sponsor_name INCYTE CORP; product OPZELURA (RUXOLITINIB PHOSPHATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215309%22

### Nov 2022: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-02-10, last confirmed 2025-04-29.
- SEC Form 10-Q (accession 0000879169-25-000056): "In November 2022, we initiated two Phase 2 trials evaluating ruxolitinib cream in lichen planus and lichen sclerosus." https://www.sec.gov/Archives/edgar/data/879169/000087916925000056/incy-20250331.htm
- SEC Form 10-K (accession 0001628280-25-004633): "In November 2022, we initiated two Phase 2 trials evaluating ruxolitinib cream in lichen planus and lichen sclerosus." https://www.sec.gov/Archives/edgar/data/879169/000162828025004633/incy-20241231.htm

### December 19, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202192 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20221219, review_priority PRIORITY; sponsor_name INCYTE CORP; product JAKAFI (RUXOLITINIB PHOSPHATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202192%22

### Mar 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month.
- First seen 2025-02-10, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0000879169-26-000066): "Also, in March 2023, we received a complete response letter for ruxolitinib extended release tablets, which identified additional requirements for approval." https://www.sec.gov/Archives/edgar/data/879169/000087916926000066/incy-20260930.htm
- SEC Form 10-Q (accession 0000879169-26-000056): "Also, in March 2023, we received a complete response letter for ruxolitinib extended release tablets, which identified additional requirements for approval." https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm
- SEC Form 10-Q (accession 0000879169-26-000026): "Also, in March 2023, we received a complete response letter for ruxolitinib extended release tablets, which identified additional requirements for approval." https://www.sec.gov/Archives/edgar/data/879169/000087916926000026/incy-20260331.htm
- SEC Form 10-K (accession 0000879169-26-000010): "Also, in March 2023, we received a complete response letter for ruxolitinib extended release tablets, which identified additional requirements for approval." https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm
- SEC Form 10-Q (accession 0000879169-25-000118): "Also, in March 2023, we received a complete response letter for ruxolitinib extended-release (XR) tablets, which identified additional requirements for approval." https://www.sec.gov/Archives/edgar/data/879169/000087916925000118/incy-20250930.htm
- SEC Form 10-Q (accession 0000879169-25-000103): "Also, in March 2023, we received a complete response letter for ruxolitinib extended-release (XR) tablets, which identified additional requirements for approval." https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm
- SEC Form 10-Q (accession 0000879169-25-000056): "Also, in March 2023, we received a complete response letter for ruxolitinib extended-release (XR) tablets, which identified additional requirements for approval." https://www.sec.gov/Archives/edgar/data/879169/000087916925000056/incy-20250331.htm
- SEC Form 10-K (accession 0001628280-25-004633): "Also, in March 2023, we received a complete response letter for ruxolitinib extended-release (XR) tablets, which identified additional requirements for approval." https://www.sec.gov/Archives/edgar/data/879169/000162828025004633/incy-20241231.htm

### Dec 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month.
- First seen 2025-02-10, last confirmed 2026-04-28.
- SEC Form 10-Q (accession 0000879169-26-000026): "In December 2023, we received FDA feedback and agreed on the requirements to address the CRL." https://www.sec.gov/Archives/edgar/data/879169/000087916926000026/incy-20260331.htm
- SEC Form 10-K (accession 0000879169-26-000010): "In December 2023, we received FDA feedback and agreed on the requirements to address the CRL." https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm
- SEC Form 10-Q (accession 0000879169-25-000118): "In December 2023, we received FDA feedback and agreed on the requirements to address the CRL." https://www.sec.gov/Archives/edgar/data/879169/000087916925000118/incy-20250930.htm
- SEC Form 10-Q (accession 0000879169-25-000103): "In December 2023, we received FDA feedback and agreed on the requirements to address the CRL." https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm
- SEC Form 10-Q (accession 0000879169-25-000056): "In December 2023, we received FDA feedback and agreed on the requirements to address the complete response letter." https://www.sec.gov/Archives/edgar/data/879169/000087916925000056/incy-20250331.htm
- SEC Form 10-K (accession 0001628280-25-004633): "In December 2023, we received FDA feedback and agreed on the requirements to address the complete response letter." https://www.sec.gov/Archives/edgar/data/879169/000162828025004633/incy-20241231.htm

### Jan 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2025-02-10, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0000879169-26-000066): "In January 2024, we announced positive topline results from a randomized controlled Phase 2 study evaluating ruxolitinib cream in hidradenitis suppurativa ("HS")." https://www.sec.gov/Archives/edgar/data/879169/000087916926000066/incy-20260930.htm
- SEC Form 10-Q (accession 0000879169-26-000056): "In January 2024, we announced positive topline results from a randomized controlled Phase 2 study evaluating ruxolitinib cream in hidradenitis suppurativa ("HS")." https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm
- SEC Form 10-Q (accession 0000879169-26-000026): "In January 2024, we announced positive topline results from a randomized controlled Phase 2 study evaluating ruxolitinib cream in hidradenitis suppurativa ("HS")." https://www.sec.gov/Archives/edgar/data/879169/000087916926000026/incy-20260331.htm
- SEC Form 10-K (accession 0000879169-26-000010): "In January 2024, we announced positive topline results from a randomized controlled Phase 2 study evaluating ruxolitinib cream in hidradenitis suppurativa ("HS")." https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm
- SEC Form 10-Q (accession 0000879169-25-000118): "In January 2024, we announced positive topline results from a randomized controlled Phase 2 study evaluating ruxolitinib cream in HS." https://www.sec.gov/Archives/edgar/data/879169/000087916925000118/incy-20250930.htm
- SEC Form 10-Q (accession 0000879169-25-000103): "In January 2024, we announced positive topline results from a randomized controlled Phase 2 study evaluating ruxolitinib cream in HS." https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm
- SEC Form 10-Q (accession 0000879169-25-000056): "In January 2024, we announced positive topline results from a randomized controlled Phase 2 study evaluating ruxolitinib cream in HS." https://www.sec.gov/Archives/edgar/data/879169/000087916925000056/incy-20250331.htm
- SEC Form 10-K (accession 0001628280-25-004633): "In January 2024, we announced positive topline results from a randomized controlled Phase 2 study evaluating ruxolitinib cream in HS." https://www.sec.gov/Archives/edgar/data/879169/000162828025004633/incy-20241231.htm

### Oct 2024: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-02-10, last confirmed 2025-02-10.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-004514): "•In October 2024, the sNDA submission for ruxolitinib cream (Opzelura®) in pediatric atopic dermatitis was filed with the FDA with approval anticipated in the second half of 2025." https://www.sec.gov/Archives/edgar/data/879169/000162828025004514/incy-q42024xexx991.htm

### 2025: trial start

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2025-02-10, last confirmed 2025-02-10.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-004514): "Incyte plans to initiate a Phase 3 monotherapy study in the post Jakafi patient population in 2025." https://www.sec.gov/Archives/edgar/data/879169/000162828025004514/incy-q42024xexx991.htm

### Apr 2025: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: moderate atopic dermatitis.
- First seen 2025-07-29, last confirmed 2025-07-29.
- Press release filed with the SEC (EX-99) (accession 0000879169-25-000100): "▪In April 2025, Incyte announced positive topline results from the Phase 3 (TRuE-AD4) study evaluating ruxolitinib cream in adult patients with moderate atopic dermatitis." https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-q22025xexx991.htm

### Jul 2025: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: moderate atopic dermatitis.
- First seen 2025-10-28, last confirmed 2026-07-28.
- SEC Form 10-Q (accession 0000879169-26-000056): "In July 2025, we announced positive topline results from the Phase 3 (TRuE-AD4) study evaluating ruxolitinib cream in adult patients with moderate AD." https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm
- SEC Form 10-Q (accession 0000879169-26-000026): "In July 2025, we announced positive topline results from the Phase 3 (TRuE-AD4) study evaluating ruxolitinib cream in adult patients with moderate atopic dermatitis." https://www.sec.gov/Archives/edgar/data/879169/000087916926000026/incy-20260331.htm
- SEC Form 10-K (accession 0000879169-26-000010): "In July 2025, we announced positive topline results from the Phase 3 (TRuE-AD4) study evaluating ruxolitinib cream in adult patients with moderate atopic dermatitis." https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm
- SEC Form 10-Q (accession 0000879169-25-000118): "In July 2025, we announced positive topline results from the Phase 3 (TRuE-AD4) study evaluating ruxolitinib cream in adult patients with moderate atopic dermatitis." https://www.sec.gov/Archives/edgar/data/879169/000087916925000118/incy-20250930.htm

### September 18, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215309 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20250918, review_priority STANDARD; sponsor_name INCYTE CORP; product OPZELURA (RUXOLITINIB PHOSPHATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215309%22

### September 19, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-07-29, last confirmed 2025-07-29.
- Press release filed with the SEC (EX-99) (accession 0000879169-25-000100): "The Prescription Drug User Fee Act (PDUFA) action date was extended by three months to September 19, 2025." https://www.sec.gov/Archives/edgar/data/879169/000087916925000100/incy-q22025xexx991.htm
- SEC Form 10-Q (accession 0000879169-25-000103): "The Prescription Drug User Fee Act (PDUFA) action date was extended by three months to September 19, 2025." https://www.sec.gov/Archives/edgar/data/879169/000087916925000103/incy-20250630.htm
- openFDA Drugs@FDA: "NDA215309 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20250918, review_priority STANDARD; sponsor_name INCYTE CORP; product OPZELURA (RUXOLITINIB PHOSPHATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215309%22

### March 3, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Leukemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02723994 (A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-03 (ACTUAL); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT02723994

### May 1, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA217180 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260501, review_priority STANDARD; sponsor_name INCYTE CORP; product JAKAFI XR (RUXOLITINIB PHOSPHATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217180%22

### August 7, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06832618 (A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-07 (ACTUAL); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06832618

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: mild to moderate hidradenitis suppurativa.
- First seen 2026-02-10, last confirmed 2026-11-16T22:20:01.192Z.
- Press release filed with the SEC (EX-99) (accession 0000879169-26-000063): "•Topline results from the Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in patients with mild to moderate hidradenitis suppurativa (HS) are anticipated in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/879169/000087916926000063/incy-q32026xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0000879169-26-000053): "•Topline results from the Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate hidradenitis suppurativa (HS) are anticipated in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/879169/000087916926000053/incy-q22026xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0000879169-26-000023): "▪Topline results from the Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate hidradenitis suppurativa (HS) are anticipated in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/879169/000087916926000023/incy-q12026xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0000879169-26-000006): "▪Topline results from the Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate hidradenitis suppurativa (HS) are anticipated in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/879169/000087916926000006/incy-q42025xexx991.htm
- SEC Form 10-Q (accession 0000879169-26-000066): "In June 2025, two Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate HS were initiated, with topline results anticipated in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/879169/000087916926000066/incy-20260930.htm
- SEC Form 10-Q (accession 0000879169-26-000056): "In June 2025, two Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate HS were initiated, with topline results anticipated in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/879169/000087916926000056/incy-20260630.htm
- SEC Form 10-Q (accession 0000879169-26-000026): "In June 2025, two Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate HS were initiated, with topline results anticipated in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/879169/000087916926000026/incy-20260331.htm
- SEC Form 10-K (accession 0000879169-26-000010): "In June 2025, two Phase 3 studies (TRuE-HS1 and TRuE-HS2) evaluating ruxolitinib cream in mild to moderate HS were initiated, with topline results anticipated in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm
- ClinicalTrials.gov: "NCT06388564 (A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-01 (ACTUAL); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06388564
- ClinicalTrials.gov: "NCT06832618 (A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-07 (ACTUAL); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06832618

### October 1, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Chronic Graft-versus-host-disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06388564 (A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-01 (ACTUAL); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06388564

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Pancreatic Cancer; Colorectal Cancer (CRC); Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02955940 (An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT02955940

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Pancreatic Cancer; Colorectal Cancer (CRC); Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02955940 (An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT02955940

## Same indication

- [Cibinqo (abrocitinib)](https://sec-api.dev/pdufa/abrocitinib) (PFE)
- [Atebimetinib](https://sec-api.dev/pdufa/atebimetinib) (IMRX)
- [ATI-045](https://sec-api.dev/pdufa/ati-045) (ACRS)
- [NIKTIMVO (axatilimab)](https://sec-api.dev/pdufa/axatilimab) (INCY)
- [Barzolvolimab](https://sec-api.dev/pdufa/barzolvolimab) (CLDX)
- [RASONQUE (daraxonrasib)](https://sec-api.dev/pdufa/daraxonrasib) (RVMD)
- [Evo756, dose 1](https://sec-api.dev/pdufa/evo756) (EVMN)
- [GHZ339](https://sec-api.dev/pdufa/ghz339) (NVS)
- [GIA632](https://sec-api.dev/pdufa/gia632) (NVS)
- [KT-621](https://sec-api.dev/pdufa/kt-621) (KYMR)
- [Lebrikizumab](https://sec-api.dev/pdufa/lebrikizumab) (LLY)
- [Lutikizumab](https://sec-api.dev/pdufa/lutikizumab) (ABBV)
- [N-803](https://sec-api.dev/pdufa/n-803) (IBRX)
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315) (PFE)
- [PF-08049820](https://sec-api.dev/pdufa/pf-08049820) (PFE)
- [RMC-6236](https://sec-api.dev/pdufa/rmc-6236) (RVMD)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [Roflumilast cream 0.3%](https://sec-api.dev/pdufa/roflumilast-cream-0-3) (ARQT)
- [Ruxolitinib cream](https://sec-api.dev/pdufa/ruxolitinib-cream) (INCY)
- [Sar444656 (kt-474)](https://sec-api.dev/pdufa/sar444656-kt-474) (SNY)
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1) (OGN)
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig) (PFE)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [Zoldonrasib](https://sec-api.dev/pdufa/zoldonrasib) (RVMD)

Calendar months: [September 2027](https://sec-api.dev/fda-calendar/2027-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ruxolitinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "JAKAFI (ruxolitinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ruxolitinib

```bibtex
@misc{secapidev_pdufa_ruxolitinib_20261116,
  title        = {JAKAFI (ruxolitinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ruxolitinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ruxolitinib_20261116","title":"JAKAFI (ruxolitinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ruxolitinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
